Positive Opioid Urine Tests Were Followed by More MOUD Starts, Not Better Persistence
A positive opioid urine drug test often appears to move treatment in the right direction, but the downstream pattern in this national cohort was uneven. Adults who tested positive were more likely to start medication for opioid use disorder within the following year, yet once treatment began, they were less likely to stay adherent. The divide between initiation and persistence is clinically important because the benefit of buprenorphine, methadone, and naltrexone depends on more than a single prescription fill or clinic visit; it depends on sustained exposure over time, when relapse risk, overdose risk, and withdrawal destabilization remain high.
This retrospective observational cohort drew from linked national laboratory and medical and pharmacy claims data across all 50 states and Washington, DC. The cohort included 759,153 adults aged 18 to 64 years with at least one opioid UDT between June 2017 and May 2025, along with continuous medical and pharmacy enrollment for 180 days before and 365 days after the initial test. The scale of the dataset gives the findings unusual reach across routine U.S. care, where UDT is frequently used as part of opioid use disorder management and broader substance use monitoring.
Overall, 32.1% of patients tested positive for opioid use. Post-UDT MOUD use remained strikingly low at 5.3% overall, and it reached only 9.4% among those with a positive opioid UDT. A single sentence captures the gap: most patients with opioid-positive testing did not transition into documented MOUD within a year. In practical terms, a test that is often intended to inform care did not reliably trigger evidence-based treatment at the population level.
Positive Testing Increased the Odds of MOUD Use, but Not Enough to Close the Treatment Gap
Multivariable logistic regression adjusted for demographics, insurance type, comorbid mental and physical health conditions, prior MOUD use, and state-level fixed effects. After those adjustments, a positive opioid UDT was associated with more than twice the odds of post-UDT MOUD use, with an odds ratio of 2.15 and a 95% confidence interval of 2.10 to 2.20. The association was consistent among patients with diagnosed opioid use disorder, which supports the clinical coherence of the result: a positive result likely signaled ongoing opioid exposure, more severe illness, or a care moment in which treatment was newly considered.
Still, the absolute uptake was modest. Relative increases can look impressive in regression models while leaving most patients untreated in real-world practice. Here, that gap is visible in the raw percentages. Even among patients with positive opioid testing, fewer than 1 in 10 received MOUD within 365 days. For a syndrome with high morbidity and mortality, that is a narrow funnel into therapy.
Biologically and behaviorally, the finding makes sense. A positive UDT may prompt clinicians to reassess relapse, ongoing opioid exposure, or failed abstinence attempts, all of which can push treatment toward agonist or antagonist therapy. But testing alone does not overcome structural barriers such as fragmented follow-up, limited access to addiction medicine, prior treatment failure, unstable housing, stigma, insurance interruptions, or inadequate same-day prescribing pathways. The laboratory result may identify risk; it does not, by itself, create continuity.
Adherence Dropped After MOUD Was Started
The more troubling signal emerged after treatment initiation. Among patients who did receive MOUD after testing, a positive opioid UDT was associated with lower odds of adherence, with an odds ratio of 0.51 and a 95% confidence interval of 0.49 to 0.54. In other words, patients with opioid-positive testing were not simply more likely to start treatment; they were also more likely to discontinue, delay, or interrupt it once started. That pattern points to a familiar failure point in addiction care: initiation without durable engagement.
The claims-based adherence definition relied on gaps consistent with prior literature, so the outcome reflects real-world medication continuity rather than a short-lived encounter or isolated dispensing event. That matters because adherence in MOUD is closely tied to stabilization, retention in care, and protection from return to use. When adherence falls, the medication’s pharmacologic buffering effect weakens. With buprenorphine, that can mean loss of receptor occupancy and renewed craving; with methadone, loss of structured opioid agonist coverage; with naltrexone, disappearance of antagonist blockade. The mechanism differs by agent, but the consequence is the same: treatment no longer protects the patient in the way it should.
The pattern also suggests that a positive UDT may identify a subgroup with greater clinical complexity. Patients with ongoing opioid exposure may enter treatment at a more unstable point, with co-occurring psychiatric illness, pain, polysubstance use, or repeated treatment exposure that makes adherence harder to maintain. The models adjusted for several of those factors, yet the association persisted, which implies that residual barriers remain embedded in the care pathway itself.
UDT as a Trigger for Care Needs Better Follow-Through
The data support a narrow but important interpretation: opioid UDT can act as a clinical trigger, but the trigger is too often followed by incomplete treatment. Positive results were associated with greater MOUD uptake, yet the overall treatment rate stayed low and adherence was worse after treatment began. That combination creates a care gap at two levels: not enough patients start therapy, and too many who start do not stay on it.
For clinicians, the implication is straightforward. UDT should not be treated as a passive monitoring tool that simply records use or abstinence. In patients with opioid-positive results, the test should prompt rapid linkage to MOUD, active follow-up, and adherence support that begins immediately rather than after the next routine visit. Systems that rely on delayed referral or fragmented handoffs are likely to lose patients during the highest-risk interval after testing.
The study also has the strengths and limits of a large administrative analysis. Its scale and national coverage make the signal hard to dismiss, but claims data cannot fully capture symptom severity, motivations for ordering the test, whether the result was discussed directly with the patient, or why a given clinician did or did not prescribe MOUD. Continuous enrollment also selects for patients who remained in the insurance system long enough to be observed, which may understate instability in the most vulnerable groups.
Even with those constraints, the central pattern is clear: a positive opioid UDT is associated with more treatment initiation and worse treatment persistence. The next step is not to ask whether testing identifies risk. It does. The more immediate question is whether care models can convert that information into rapid, sustained MOUD engagement before the opportunity for stabilization slips away.